Table 3.
Predicted % LDL-C lowering from baseline to week 12 by statins alone and in combination with bempedoic acid
| Mean (90% CI) LDL-C % change from baselinea | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atorvastatin | Simvastatin | Rosuvastatin | Pravastatin | |||||||||
| Statin dose (mg) | Alone | + BA 180 mg | ΔLDL-Cb | Alone | + BA 180 mg | ΔLDL-Cb | Alone | + BA 180 mg | ΔLDL-Cb | Alone | + BA 180 mg | ΔLDL-Cb |
| 0 | — | −27 (−29, −26) | — | — | −27 (−29, −26) | — | — | −27 (−29, −26) | — | — | −27 (−29, −26) | — |
| 10 | −37 (−40, −30) | −51 (−55, −46) | −22 | −30 (−36, −23) | −46 (−50, −42) | −23 | −46 (−55, −39) | −57 (−62, −52) | −20 | −21 (−26, −16) | −41 (−45, −37) | −25 |
| 20 | −43 (−51, −36) | −54 (−60, −50) | −19 | −36 (−43, −29) | −50 (−54, −45) | −22 | −52 (−61, −44) | −60 (−66, −55) | −17 | −26 (−32, −20) | −44 (−48, −39) | −24 |
| 40 | −49 (−57, −41) | −58 (−63, −53) | −18 | −42 (−50, −34) | −54 (−59, −49) | −21 | −57 (−66, −49) | −63 (−69, −58) | −14 | −32 (−38, −25) | −47 (−52, −43) | −22 |
| 80 | −54 (−63, −46) | −62 (−67, −56) | −17 | — | — | — | — | — | — | −38 (−45, −31) | −51 (−56, −46) | −21 |
BA, bempedoic acid; LDL-C, LDL cholesterol.
a
Data represent 1000 simulations using bootstrapped data and parameter estimates.
b
ΔLDL-C represents the % reduction in LDL-C due to bempedoic acid when added to stable background therapy at the designated statin dose.